Bioequivalence Study of Pimavanserin 34 mg Capsule

Parkinson Disease Psychosis Clinical Trial

Official title:
An Open-label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Two Way Cross-over, Single Dose Bioequivalence Study of Pimavanserin 34 mg Capsule of Humanis Sağlık A.Ş., Turkey and NUPLAZID® (Pimavanserin) Capsules of Acadia Pharmaceuticals Inc. San Diego, CA 92130 USA in Normal, Healthy, Adult, Human Subjects Under Fasting Condition

Status Completed

Clinical Trial Summary

An open-label, balanced, randomized, two treatment, two sequence, two period, two way cross-over, single dose bioequivalence study of Pimavanserin 34 mg Capsule of Humanis Sağlık A.Ş., Turkey and NUPLAZID® (Pimavanserin) capsules of Acadia Pharmaceuticals Inc. San Diego, CA 92130 USA in normal, healthy, adult, human subjects under fasting condition.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06450184
Study type	Interventional
Source	Humanis Saglik Anonim Sirketi
Contact
Status	Completed
Phase	Phase 1
Start date	January 11, 2024
Completion date	March 9, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05824728` - Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis	Phase 2
Terminated	`NCT03152292` - The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
Withdrawn	`NCT05344365` - A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis	Phase 2
Recruiting	`NCT05357612` - Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases	Phase 4
Completed	`NCT04292223` - Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis	Phase 4
Completed	`NCT02969369` - A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis	Phase 2
Not yet recruiting	`NCT05995782` - A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418	Phase 1
Recruiting	`NCT04592965` - Hallucinations in Parkinson's Disease	N/A
Recruiting	`NCT04579887` - Presence Hallucination in Parkinson's Disease	N/A
Completed	`NCT05240339` - Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
Recruiting	`NCT03661125` - SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis	Early Phase 1